This variable effect of the drugs may be due to the heterogenicity of breast cancer and could also be related to resistance mechanisms, such as increased activity of the ATP-binding cassette transporters, as reported in human breast cancer [100,101]. This evidence concerns the gene ABCA4 and breast cancer.